NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
16 Maio 2023 - 9:30AM
NurExone Biologic Inc. (the "
Company" or
"
NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a
biopharmaceutical company developing biologically-guided exosome
therapy for patients with traumatic spinal cord injuries, announces
that the Company has received an issue notification from the United
States Patent and Trademark Office (“USPTO”) for U.S. Patent NO.
11,648,260, granted for the period of 20 years from filing date
until March 27, 2039. The patent protects NurExone’s Exo-PTEN
technology, and its drug composition as well as methods for
non-invasive intranasal administration of exosome-based treatment.
The Patent is a result of a productive
collaboration between the Technion (the Israel Institute of
Technology) and Tel Aviv University. Both Technology transfer
companies, Technion Research and Development Foundation Ltd. and
Ramot at Tel Aviv University Ltd are the assignees on the granted
patent. NurExone has an exclusive license on the granted patent.
One of the inventors, Dr. Nisim Perets is currently leading the
technology transfer activities in NurExone’s research and
development team.
In order to strengthen the Exo-PTEN technology
platform protection as well as to further expand NurExone’s
intellectual property portfolio, the Company proceeds in a filing
of a child ‘continuation’ patent application with the USPTO, to
include additional claims on the method of treatment and indication
of the Exo-PTEN platform. In parallel, counterparts of the U.S.
patent are being examined in different countries around the
world.
According to Patent Attorney Bat Ami Gotliv,
PhD, who consults the Company - the grant of this patent is a
significant millstone for NurExone and, based on the Company’s
promising Intellectual Property portfolio, an initial step for
expanding its proprietary estate and becoming a leading company in
the field of Central Nervous System and neurological diseases
treatment.
“We are pleased to have been granted a patent
for our propriety drug product, Exo-PTEN,” said Dr. Lior Shaltiel,
CEO of NurExone. “The latest patent expands our intellectual
property portfolio and enables us to be the exclusive provider of
this unique exosome-based therapy that is designed to treat acute
spinal cord injuries.”
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSX Venture
Exchange-listed pharmaceutical company that is developing a
platform for biologically-guided ExoTherapy to be delivered,
non-invasively, to patients who suffered traumatic spinal cord
injuries.
ExoTherapy was conceptually demonstrated in animal studies at
the Technion, Israel Institute of Technology. NurExone is
translating the treatment to humans, and the Company holds an
exclusive worldwide license from the Technion and Tel Aviv
University for the development and commercialization of the
technology.
For additional information, please
visit www.nurexone.com or follow NurExone on LinkedIn,
Twitter, Facebook, or YouTube.
For further information, please
contact:
Dr. Lior ShaltielChief Executive Officer and
DirectorPhone: +972-52-4803034
Inbar Paz-Benayoun, Adv. Head of Communications
and Investor RelationsPhone:
+972-52-3966695Email: info@nurexone.com
Investor Relations (Canada)Phone: +1
905-347-5569Email: IR@nurexone.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024